Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | AML post-transplant maintenance: enasidenib & ivosidenib

Amir Fathi • 24 Nov 2020
ASH 2020
Acute Myeloid Leukemia Leukemia Enasidenib Ivosidenib

Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA outlines the findings of two dose-escalation and expansion studies. One of the trials investigated the use of the IDH1 inhibitor ivosidenib in IDH1-mutated acute myeloid leukemia (AML) patients. The other looked at the use of enasidenib (ENA) in IDH2-mutated AML. Both trials investigate these regimens in the post-transplant maintenance setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Amir Fathi

A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026
Community-academic collaboration in AML management
1:08
Community-academic collaboration in AML management
Amir Fathi • 21 Sep 2026
Sequencing targeted therapies in AML with multiple targetable alterations
0:51
Sequencing targeted therapies in AML with multiple targetable alterations
Amir Fathi • 21 Sep 2026
KOMET-007 trial results: ziftomenib combinations in NPM1-mutated and KMT2A-rearranged AML
1:31
KOMET-007 trial results: ziftomenib combinations in NPM1-mutated and KMT2A-rearranged AML
Amir Fathi • 21 Sep 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals